Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib Malate in Refractory Germ Cell Tumors
NCT00912912Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2009
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib in germ cell tumor (GCT), sponsored by University of Texas MD Anderson Cancer Center. Started May 2009; status: terminated.
02
Drugs
sunitinib
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT00912912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00912912.